Data from Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer
Martin Smoragiewicz, Alice Bernard‐Tessier, Mark David Linch, John Shen et autres
Abstract Purpose: Resistance to androgen receptor (AR) pathway inhibitors necessitates the development of regimens to improve outcomes in metastatic prostate cancer (mPC). This phase Ib clinical trial evaluated the safety/tolerability and pharmacokinetics of bavdegalutamide, an oral proteolysis-targeting chimera AR degrader, combined with …